Identifying Sleep Apnea Patients That Best Respond to Atomoxetine Plus Oxybutynin Therapy
Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
Atomoxetine-plus-oxybutynin therapy (AtoOxy) has been shown to substantially reduce
obstructive sleep apnea severity (OSA) in about half of patients. Here, the investigators
study which patients respond meaningfully to therapy using pathophysiological traits measured
at baseline sleep studies.